{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:06:10Z","timestamp":1789664770022,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1124\/molpharm.120.000083","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T01:15:24Z","timestamp":1606353324000},"page":"125-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Molecular Mechanisms for the Inflammation-Resolving Actions of Lenabasum"],"prefix":"10.1016","volume":"99","author":[{"given":"Sumner","family":"Burstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/molpharm.120.000083_bib1","doi-asserted-by":"crossref","first-page":"18625","DOI":"10.1074\/jbc.M702538200","article-title":"Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma","volume":"282","author":"Ambrosio","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1124\/molpharm.120.000083_bib2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1165\/rcmb.2002-0162OC","article-title":"Retrovirally introduced prostaglandin D2 synthase suppresses lung injury induced by bleomycin","volume":"28","author":"Ando","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1124\/molpharm.120.000083_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1521-6616(03)00064-0","article-title":"Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes","volume":"108","author":"Bidinger","year":"2003","journal-title":"Clin Immunol"},{"key":"10.1124\/molpharm.120.000083_bib4","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/0006-2952(94)90163-5","article-title":"Phospholipase participation in cannabinoid-induced release of free arachidonic acid","volume":"48","author":"Burstein","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/molpharm.120.000083_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1126\/science.176.4033.422","article-title":"Isolation and characterization of two major urinary metabolites of 1 -tetrahydrocannabinol","volume":"176","author":"Burstein","year":"1972","journal-title":"Science"},{"key":"10.1124\/molpharm.120.000083_bib6","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1002\/art.20805","article-title":"Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al","volume":"50","author":"Burstein","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1124\/molpharm.120.000083_bib7","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/j.bmc.2019.05.018","article-title":"Eicosanoid mediation of cannabinoid actions","volume":"27","author":"Burstein","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/molpharm.120.000083_bib8","article-title":"The chemistry, biology and pharmacology of the cyclopentenone prostaglandins","volume":"148","author":"Burstein","year":"2020","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1124\/molpharm.120.000083_bib9","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1021\/jm00095a007","article-title":"Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities","volume":"35","author":"Burstein","year":"1992","journal-title":"J Med Chem"},{"key":"10.1124\/molpharm.120.000083_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0024-3205(98)00256-2","article-title":"Analgesic effects of 1\u2032,1\u2032 dimethylheptyl-delta8-THC-11-oic acid (CT3) in mice","volume":"63","author":"Burstein","year":"1998","journal-title":"Life Sci"},{"key":"10.1124\/molpharm.120.000083_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/83336","article-title":"PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation","volume":"7","author":"Chawla","year":"2001","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"10.1124\/molpharm.120.000083_bib54","first-page":"1372","article-title":"Lenabasum, A Cb2 agonist, inhibits inflammasome activation","volume":"79","author":"Chintalacharuvu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/molpharm.120.000083_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)35067-0","article-title":"1\u2032,1\u2032-Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties","volume":"291","author":"Dajani","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.120.000083_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/microbiolspec.MCHD-0001-2014","article-title":"Macrophage proresolving mediators-the when and where","volume":"4","author":"Dalli","year":"2016","journal-title":"Microbiol Spectr"},{"key":"10.1124\/molpharm.120.000083_bib14","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1016\/S0021-9258(17)36794-7","article-title":"Diversity of group types, regulation, and function of phospholipase A2","volume":"269","author":"Dennis","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1124\/molpharm.120.000083_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pain.2005.03.037","article-title":"Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat","volume":"116","author":"Dyson","year":"2005","journal-title":"Pain"},{"key":"10.1124\/molpharm.120.000083_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.pharmtox.38.1.179","article-title":"Cannabinoid receptors and their endogenous agonists","volume":"38","author":"Felder","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/molpharm.120.000083_bib17","first-page":"189","article-title":"Prostaglandin J2--anti-tumour and anti-viral activities and the mechanisms involved","volume":"3","author":"Fukushima","year":"1990","journal-title":"Eicosanoids"},{"key":"10.1124\/molpharm.120.000083_bib18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/jcp.21263","article-title":"Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells","volume":"214","author":"George","year":"2008","journal-title":"J Cell Physiol"},{"key":"10.1124\/molpharm.120.000083_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s001090000094","article-title":"New insights into the role of COX 2 in inflammation","volume":"78","author":"Gilroy","year":"2000","journal-title":"J Mol Med (Berl)"},{"key":"10.1124\/molpharm.120.000083_bib20","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","article-title":"Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis","volume":"71","author":"Gonzalez","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/molpharm.120.000083_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.urology.2007.02.069","article-title":"Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats","volume":"70","author":"Hiragata","year":"2007","journal-title":"Urology"},{"key":"10.1124\/molpharm.120.000083_bib22","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/BF00966122","article-title":"Effects of cannabinoids on the activities of mouse brain lipases","volume":"11","author":"Hunter","year":"1986","journal-title":"Neurochem Res"},{"key":"10.1124\/molpharm.120.000083_bib23","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1124\/jpet.107.124214","article-title":"Comments on \u201ccannabimimetic properties of ajulemic acid\u201d","volume":"322","author":"Karst","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.120.000083_bib24","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/jama.290.13.1757","article-title":"Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial","volume":"290","author":"Karst","year":"2003","journal-title":"JAMA"},{"key":"10.1124\/molpharm.120.000083_bib25","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1124\/molpharm.120.000083_bib26","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1124\/mol.63.5.983","article-title":"Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid","volume":"63","author":"Liu","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.120.000083_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12931-016-0373-0","article-title":"Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung","volume":"17","author":"Lucattelli","year":"2016","journal-title":"Respir Res"},{"key":"10.1124\/molpharm.120.000083_bib28","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.4049\/jimmunol.1401611","article-title":"The cyclopentenone prostaglandin 15d-PGJ2 inhibits the NLRP1 and NLRP3 inflammasomes","volume":"194","author":"Maier","year":"2015","journal-title":"J Immunol"},{"key":"10.1124\/molpharm.120.000083_bib29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.redox.2015.08.006","article-title":"The role of lipoxygenases in pathophysiology; new insights and future perspectives","volume":"6","author":"Mashima","year":"2015","journal-title":"Redox Biol"},{"key":"10.1124\/molpharm.120.000083_bib30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neulet.2005.03.019","article-title":"Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain","volume":"382","author":"Mitchell","year":"2005","journal-title":"Neurosci Lett"},{"key":"10.1124\/molpharm.120.000083_bib31","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cpt.980","article-title":"Potent anti-inflammatory and pro-resolving effects of anabasum in a human model of self-resolving acute inflammation","volume":"104","author":"Motwani","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/molpharm.120.000083_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/187152806776383125","article-title":"Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation","volume":"5","author":"Parkinson","year":"2006","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1124\/molpharm.120.000083_bib33","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0006-2952(01)00700-6","article-title":"Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid","volume":"62","author":"Recht","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/molpharm.120.000083_bib34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jmb.2017.10.028","article-title":"Caspase-1 is an apical caspase leading to caspase-3 cleavage in the AIM2 inflammasome response, independent of caspase-8","volume":"430","author":"Sagulenko","year":"2018","journal-title":"J Mol Biol"},{"key":"10.1124\/molpharm.120.000083_bib35","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.neuropharm.2005.02.010","article-title":"Pain measurements and side effect profile of the novel cannabinoid ajulemic acid","volume":"48","author":"Salim","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.120.000083_bib36","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2310\/JIM.0b013e31819aaa76","article-title":"The anti-inflammatory effects of prostaglandins","volume":"57","author":"Scher","year":"2009","journal-title":"J Investig Med"},{"key":"10.1124\/molpharm.120.000083_bib37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"10.1124\/molpharm.120.000083_bib38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1100\/tsw.2002.81","article-title":"Lipid-derived mediators in endogenous anti-inflammation and resolution: lipoxins and aspirin-triggered 15-epi-lipoxins","volume":"2","author":"Serhan","year":"2002","journal-title":"ScientificWorldJournal"},{"key":"10.1124\/molpharm.120.000083_bib39","first-page":"1","article-title":"Lipoxins: a new series of eicosanoids (biosynthesis, stereochemistry, and biological activities)","volume":"229","author":"Serhan","year":"1988","journal-title":"Adv Exp Med Biol"},{"key":"10.1124\/molpharm.120.000083_bib40","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/ni1276","article-title":"Resolution of inflammation: the beginning programs the end","volume":"6","author":"Serhan","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1124\/molpharm.120.000083_bib41","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1016\/S0021-9258(18)50582-2","article-title":"Purification and properties of prostaglandin D synthetase from rat brain","volume":"254","author":"Shimizu","year":"1979","journal-title":"J Biol Chem"},{"key":"10.1124\/molpharm.120.000083_bib42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/imr.12839","article-title":"Inflammasomes contributing to inflammation in arthritis","volume":"294","author":"Spel","year":"2020","journal-title":"Immunol Rev"},{"key":"10.1124\/molpharm.120.000083_bib43","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and efficacy of lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1124\/molpharm.120.000083_bib44","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.lfs.2008.09.004","article-title":"Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells","volume":"83","author":"Stebulis","year":"2008","journal-title":"Life Sci"},{"key":"10.1124\/molpharm.120.000083_bib45","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/art.20050","article-title":"A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis","volume":"50","author":"Sumariwalla","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1124\/molpharm.120.000083_bib46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrm2312","article-title":"Apoptosis: controlled demolition at the cellular level","volume":"9","author":"Taylor","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/molpharm.120.000083_bib47","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/j.bmc.2014.04.062","article-title":"Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity","volume":"22","author":"Tepper","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/molpharm.120.000083_bib48","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1124\/jpet.106.111625","article-title":"Cannabimimetic properties of ajulemic acid","volume":"320","author":"Vann","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.120.000083_bib49","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0014-5793(95)00027-7","article-title":"The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide","volume":"359","author":"Wartmann","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1124\/molpharm.120.000083_bib50","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1096\/fj.201600646R","article-title":"Cannabinoids, inflammation, and fibrosis","volume":"30","author":"Zurier","year":"2016","journal-title":"FASEB J"},{"key":"10.1124\/molpharm.120.000083_bib51","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-2952(02)01604-0","article-title":"Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid","volume":"65","author":"Zurier","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/molpharm.120.000083_bib52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/1529-0131(199801)41:1<163::AID-ART20>3.0.CO;2-9","article-title":"Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure","volume":"41","author":"Zurier","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1124\/molpharm.120.000083_bib53","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1096\/fj.08-118323","article-title":"Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4","volume":"23","author":"Zurier","year":"2009","journal-title":"FASEB J"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24010861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24010861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/molpharm.120.000083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T05:35:44Z","timestamp":1739943344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24010861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0026895X24010861"],"URL":"https:\/\/doi.org\/10.1124\/molpharm.120.000083","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Mechanisms for the Inflammation-Resolving Actions of Lenabasum","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/molpharm.120.000083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}